MindWalk (NASDAQ:HYFT) Announces Earnings Results

MindWalk (NASDAQ:HYFT) released its quarterly earnings results on Wednesday. The company reported ($0.06) earnings per share (EPS) for the quarter, FiscalAI reports. MindWalk had a negative net margin of 66.79% and a negative return on equity of 69.37%. The business had revenue of $3.03 million for the quarter.

MindWalk Stock Performance

NASDAQ HYFT traded down $0.02 on Wednesday, hitting $1.44. 192,991 shares of the stock were exchanged, compared to its average volume of 407,074. The company has a quick ratio of 3.64, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. MindWalk has a 52-week low of $0.99 and a 52-week high of $3.25. The stock has a market capitalization of $67.27 million, a price-to-earnings ratio of -7.20 and a beta of 0.83. The business has a fifty day moving average price of $1.55.

Analysts Set New Price Targets

HYFT has been the topic of a number of research reports. JonesTrading assumed coverage on shares of MindWalk in a report on Thursday, April 16th. They issued a “buy” rating and a $5.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of MindWalk in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, MindWalk has an average rating of “Moderate Buy” and an average target price of $5.00.

Institutional Investors Weigh In On MindWalk

Institutional investors have recently made changes to their positions in the company. Jane Street Group LLC raised its position in MindWalk by 147.3% in the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after purchasing an additional 96,018 shares during the period. Bridgeway Capital Management LLC purchased a new position in MindWalk during the 4th quarter valued at $91,000. XTX Topco Ltd grew its position in MindWalk by 118.6% in the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after acquiring an additional 44,331 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of MindWalk during the fourth quarter valued at $51,000. Finally, Bank of Montreal Can grew its holdings in shares of MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after purchasing an additional 24,500 shares during the last quarter. Institutional investors own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.